Correlation between Low-Density Lipoprotein Cholesterol and Certain Lipid Profiles in The Treatment of Bay Leaf Extract (Syzgium Polyanthum (Wight) Walp) to Dyslipidemia Patients

Authors

  • Melati Silvanni Nasution Divisi Endokrin, Depatemen Ilmu Penyakit Dalam FK-USU
  • Brama Ihsan Sazli Endocrine, Metabolic and Diabetes Division, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Santi Syafril Endocrine, Metabolic and Diabetes Division, Department of Internal Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.32734/jetromi.v5i2.12244

Keywords:

LDL-C, Bay Leaf Extract (Syzgium Polyanthum (Wight) Walp)

Abstract

Background: The use of herbal medicine has long been practiced throughout the world, and the production and processing of herbal medicines are constantly being improved to treat various diseases. The aim of this study was to assess the correlation between low density lipoprotein cholesterol and certain lipid profiles in the treatment of bay leaf extract (syzgium polyanthum (wight) walp) to dyslipidemia patients.

Method: We recruit dyslipidemia patients, and the search project was given an explanation and asked to give written consent (informed consent) to participate in the research. Then anamnes is carried out and examination:measurement of BMI, measurement  of weist circumference, after being satisfied for 10-12 hours, the  patient then took blood samples by the laboratory, to examine hs-CRP levels, lipid profiles (total  cholesterol,  LDL cholesterol, HDL cholesterol  and triglycerides), routine blood, kidney function (ureum, creatinine). Blood samples is taken before and after 30 days study. Bay leaf extract 150 mg is taken two times perday .

Result: Subjects who participate of the study were 15 peoples as a treatment group and ages 47.47±11,507 years old. There is signifikant differences in cholesterol total, LDL-C and Apo=B (all, p < 0,01). There is a correlation between LDL-C and Total Cholesrerol, Triglyceride, FPG and Apo-B (all, p < 0.05).

Conclusion: In this study, bay leaf administration 2x150 mg for 30 days, improved lipid profiles of total cholesterol, LDL, and ApoB in dyslipidemic patients. Bay leaf extract administration has the potential to prevent and improve cardiovascular disease in dyslipidemic patients

Downloads

Download data is not yet available.

Published

2023-07-08